EpiVax Oncology's Option/Warrant Round

EpiVax Oncology raised a round of funding on December 11, 2017.

EpiVax Oncology (EO) is developing precision cancer immunotherapies based on Neo-Epitopes selected using proprietary and validated, in silico, predictive algorithms. Using genetic profiling (via NGS S…

Articles about EpiVax Oncology's Option/Warrant Round: